GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Wohua Pharmaceutical Co Ltd (SZSE:002107) » Definitions » 3-Year FCF Growth Rate

Shandong Wohua Pharmaceutical Co (SZSE:002107) 3-Year FCF Growth Rate : -4.50% (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Shandong Wohua Pharmaceutical Co 3-Year FCF Growth Rate?

Shandong Wohua Pharmaceutical Co's Free Cash Flow per Share for the three months ended in Mar. 2024 was ¥0.11.

During the past 12 months, Shandong Wohua Pharmaceutical Co's average Free Cash Flow per Share Growth Rate was 1.80% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -4.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Shandong Wohua Pharmaceutical Co was 332.70% per year. The lowest was -28.20% per year. And the median was 10.75% per year.


Competitive Comparison of Shandong Wohua Pharmaceutical Co's 3-Year FCF Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Shandong Wohua Pharmaceutical Co's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shandong Wohua Pharmaceutical Co's 3-Year FCF Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shandong Wohua Pharmaceutical Co's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Shandong Wohua Pharmaceutical Co's 3-Year FCF Growth Rate falls into.



Shandong Wohua Pharmaceutical Co 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Shandong Wohua Pharmaceutical Co  (SZSE:002107) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Shandong Wohua Pharmaceutical Co 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Shandong Wohua Pharmaceutical Co's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Wohua Pharmaceutical Co (SZSE:002107) Business Description

Traded in Other Exchanges
N/A
Address
Fushou East Street, Chuangye Building, 2F, New and High-Tech Industrial Development Zone, Huaifang, Shandong, CHN, 261011
Shandong Wohua Pharmaceutical Co Ltd is a China-based company specializing in the field of cardio-cerebral vascular medicine. The company's main products consist of Xinkeshu tablets for the treatment of coronary heart disease; Naoxueshu oral liquid, promoting blood circulation by removing blood stasis; Hupo Xiaoshi granules for the treatment of urethral calculus, and Yuandu granules for the treatment of influenza, among others.
Executives
Zhao Jun Director
Liu Wen Yi Supervisors
Zhang Fa Zhong Supervisors
Zhang Ge Director
Ma Xing Chen Supervisors
Tian Kai Ji Directors, executives
Kong Xian Jun Supervisors

Shandong Wohua Pharmaceutical Co (SZSE:002107) Headlines

No Headlines